PDF Archive

Easily share your PDF documents with your contacts, on the Web and Social Networks.

Share a file Manage my documents Convert Recover PDF Search Help Contact



cvfile 0023229.pdf


Preview of PDF document cvfile-0023229.pdf

Page 1 2 3 4 5 6

Text preview


- Randomized phase II study of lapatinib plus vinorelbine versus vinorelbine in patients with HER2
positive metastatic breast cancer progressed after lapatinib and trastuzumab treatment, IIT, 2012,
Sub-investigator [LV]
- A randomized, double-blind, placebo controlled, phase II study of BKM120 plus paclitaxel in
patients with HER2 negative inoperable locally advanced or metastatic breast cancer, with or
without PI3K pathway activation, sponsored by Novartis, 2012, Sub-investigator[BELLE4]
- An open label, phase II trial of afatinib with or without vinorelbine for the treatment of
HER2-overexpressing Inflammatory Breast Cancer, sponsored by Boehringer Ingelheim, 2012,
Sub-investigator[BIBW1200.89]
- A phase III prospective, 2-cohort, non-randomized, multi-center, multinational, open label study
to assess the safety of assisted-and self-administered subcutaneous trastuzumab ad adjuvant
therapy in patients with operable HER2-positive early breast cancer, sponsored by ROCHE, 2012,
sub-investigator[SafeHer]
- A randomized multicenter, double-blind, placebo-controlled comparison of chemotherapy plus
trastuzumab plus placebo versus chemotherapy plus trastuzumab plus pertuzumab as adjuvant
therapy in patients with operable HER2-positive primary breast cancer, sponsored by Roche, 2011,
Sub-investigator[APHINITY]
- Phase III multicenter Randomized Open-label study of irinotecan plus CapEcitabine versus
capEcitabine in patients previously treateD with anthracycline and taxane for HER2 negative
metastatic breast cancer, IIT, 2011, Principal investigator [PROCEED]
- A phase III randomized, multicenter, 2-arm, open-label trial to evaluate the efficacy of T-DM1
compared with treatment of physician’s choice in patients with HER2-positive metastatic breast
cancer who have received at least 2 prior regimens of HER2-directed therapy, sponsored by Roche,
2011, Sub-investigator[THERESA]
- A Phase III trial to compare the safety and efficacy of lapatinib plus trastuzumab plus an
aromatase inhibitor (AI) versus trastuzumab plus an AI versus lapatinib plus an AI as 1st-line
therapy in postmenopausal subjects with hormone receptor positive, HER2-positive metastatic
breast cancer (MBC) who have received trastuzumab and endocrine therapy in the neoadjuvant
and/or adjuvant setting, sponsored by GSK, 2011, Sub-investigator[EGF114299]
- A randomized, Double-Bline, Placebo-Controlled, Multi-Center Phase 3 Study of Denosumab as
Adjuvant Treatment for Women with Early-Stage Breast Cancer at High Risk of Recurrence,
sponsored by Amgen, 2011, sub-investigator[D-CARE]
- A phase II trial of NEoadjuvant bevAcizumab, docetaxel and carboplatin for Triple negative
breast cancer(NEAT trial). 2011, sub-investigator
- A multi-center, randomized phase II, 3-arm, open-lavel study of goserelin plus fulvestrant versus
goserelin plus anastrozole versus goserelin alone for hormone receptor-positive, tamoxifen
pretreated, premenopausal women with recurrent or metastatic breast cancer.(FLAG) 2010,
sub-investigator
- Phase 1/2, open-label, randomized study of the safety, efficacy, and pharmacokinetics of
Letrozole plus PD 0332991 (Oral CDK 4/6 inhibitor) and Letrozole single agent for the 1st line
treatment of ER positive, HER2 negative advanced Breast cancer in postmenopausal women,
sponsored by Pfizer, 2010, Sub-investigator [A5481003]
- A two-part,adaptive,randomized trial of ridaforolimus in combination with dalotuzumab
coapared to exemestane or compared to ridaforolimus or dalotuzumab monotherapy in estrogen
receptor positive breast cancer patients, sponsored by MSD, 2010, Principal investigator

-3-